Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cancer Biomarker Testing Market: By Type Of Cancer, By Application, By End-User and Geography
Cancer Biomarker Testing Market Size was valued at US$ 10.42 billion in 2023 and is poised to grow at a significant CAGR of 15.4% from 2024-2030. The cancer biomarker test market is driven by The increasing use of cancer biomarkers in drug discovery and development, along with growing research in this area, technological advancements, and the rising global incidence of cancer, are all contributing to significant advancements in cancer diagnosis, treatment, and patient care. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades.
In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO's funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market. and Regulatory agencies like the U.S. Food and Drug Administration (FDA) were providing guidance on the development and validation of biomarkers for clinical use. Streamlining regulatory pathways for biomarker-based tests was important for their clinical adoption. The global market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share.
Study Period
2024-2030Base Year
2023CAGR
15.4%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Companion diagnostics, tailored medications, and other disease diagnostics, such as disease risk assessment and drug research and development, all rely heavily on cancer biomarkers. One of the primary reasons likely to boost cancer biomarkers market growth during the projected period of 2024-2030 is the increased utilisation of biomarkers in disease diagnosis. The rising global prevalence of cancer is driving the need for early disease detection, which is propelling the market forward.
According to the National Cancer Institute, 1,735,350 new cancer cases were reported in the United States in 2018. In addition, the World Cancer Research Fund International estimates that 18.0 million individuals worldwide were affected by cancer in 2018. Lung and breast cancers were the most prevalent cancers reported globally in 2018, accounting for 12.3 percent of all cases diagnosed. The increased incidence of cancer biomarkers in both developing and developed countries is expected to boost demand for cancer diagnostics and therapy. During the projection period these factors are expected to boost demand for these biomarkers.
Despite the rising global incidence of cancer and the increasing number of patients requiring diagnostic tests, the lack of reimbursement regulations for biomarker tests in emerging and industrialised nations is one issue restricting global demand for these biomarkers. Another key stumbling block to the market's expansion is the high cost of cancer diagnosis and treatment in developing countries. This is reducing the number of patients who are tested for biomarkers, and patients are increasingly preferring other low-cost detection tests. As immunotherapy gained prominence as a cancer treatment approach, identifying biomarkers that could predict patient responses to immunotherapies (such as PD-L1 expression) became crucial for optimizing treatment strategies.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 10.42 billion |
Market CAGR |
15.4% |
By Type of Cancer |
|
By Application |
|
By End User |
|
By Region |
|
Download Free Sample Report
The Cancer Biomarker Testing Market was expected to grow at a significant compound annual growth rate (CAGR) of 15.4% from 2024 to 2030. Additionally, it mentions that the market value was US$ 10.42 billion in 2030.
Thermo Fisher Scientific (Affymetrix Inc.), Abbott Laboratories, F. Hoffmann-La Roche Ltd., AbbVie Inc.Arquer Diagnostics Ltd., Illumina, Inc.
Asia-Pacific is the fastest-growing region for the market.
1.Executive Summary |
2.Global Cancer Biomarker Testing Market Introduction |
2.1.Global Cancer Biomarker Testing Market - Taxonomy |
2.2.Global Cancer Biomarker Testing Market - Definitions |
2.2.1.Type of Cancer |
2.2.2. Application |
2.2.3. End User |
2.2.4.Region |
3.Global Cancer Biomarker Testing Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Cancer Biomarker Testing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Cancer Biomarker Testing Market By Type of Cancer, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Cervical cancer |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Lung Cancer |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Collateral Cancer |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Liver Cancer |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Prostate Cancer |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Breast Cancer |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6.Global Cancer Biomarker Testing Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Drug Discovery and Development |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Personalised Medicine |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Diagnosis |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Cancer Biomarker Testing Market By End User , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Cancer diagnostic Centres |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Research Institutes |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Cancer Biomarker Testing Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type of Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Cervical cancer |
9.1.2.Lung Cancer |
9.1.3.Collateral Cancer |
9.1.4.Liver Cancer |
9.1.5.Prostate Cancer |
9.1.6.Breast Cancer |
9.1.7.Others |
9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Drug Discovery and Development |
9.2.2.Personalised Medicine |
9.2.3.Diagnosis |
9.2.4.Others |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Cancer diagnostic Centres |
9.3.3.Research Institutes |
9.3.4.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type of Cancer Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Cervical cancer |
10.1.2.Lung Cancer |
10.1.3.Collateral Cancer |
10.1.4.Liver Cancer |
10.1.5.Prostate Cancer |
10.1.6.Breast Cancer |
10.1.7.Others |
10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Drug Discovery and Development |
10.2.2.Personalised Medicine |
10.2.3.Diagnosis |
10.2.4.Others |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Cancer diagnostic Centres |
10.3.3.Research Institutes |
10.3.4.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type of Cancer Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Cervical cancer |
11.1.2.Lung Cancer |
11.1.3.Collateral Cancer |
11.1.4.Liver Cancer |
11.1.5.Prostate Cancer |
11.1.6.Breast Cancer |
11.1.7.Others |
11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Drug Discovery and Development |
11.2.2.Personalised Medicine |
11.2.3.Diagnosis |
11.2.4.Others |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Cancer diagnostic Centres |
11.3.3.Research Institutes |
11.3.4.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type of Cancer Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Cervical cancer |
12.1.2.Lung Cancer |
12.1.3.Collateral Cancer |
12.1.4.Liver Cancer |
12.1.5.Prostate Cancer |
12.1.6.Breast Cancer |
12.1.7.Others |
12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Drug Discovery and Development |
12.2.2.Personalised Medicine |
12.2.3.Diagnosis |
12.2.4.Others |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Cancer diagnostic Centres |
12.3.3.Research Institutes |
12.3.4.Others |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Cancer Biomarker Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type of Cancer Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Cervical cancer |
13.1.2.Lung Cancer |
13.1.3.Collateral Cancer |
13.1.4.Liver Cancer |
13.1.5.Prostate Cancer |
13.1.6.Breast Cancer |
13.1.7.Others |
13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Drug Discovery and Development |
13.2.2.Personalised Medicine |
13.2.3.Diagnosis |
13.2.4.Others |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Cancer diagnostic Centres |
13.3.3.Research Institutes |
13.3.4.Others |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Thermo Fisher Scientific (Affymetrix Inc.) (U.S.) |
14.2.2.Abbott Laboratories (U.S.) |
14.2.3.F. Hoffmann-La Roche Ltd. (Switzerland) |
14.2.4.AbbVie Inc. (U.S.) |
14.2.5.Arquer Diagnostics Ltd. (U.K.) |
14.2.6.Illumina, Inc. (U.S.) |
14.2.7.Qiagen (Germany) |
14.2.8.Agilent Technologies (U.S.) |
14.2.9.Merck & Co. Inc. (U.S.) |
14.2.10.Becton Dickinson and Company (U.S.) |
14.2.11.Hologic Inc. (U.S.) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players